ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2147

Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease

Waleed Hafiz1, Nan-Hua Chang2, Babak Noamani3, Dennisse Bonilla3, Larissa Lisnevskaia4, Earl Silverman5, Arthur Bookman6, Sindhu R. Johnson7, Carolina Landolt-Marticorena3 and Joan Wither3, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Lakeridge Health Services, Oshawa, ON, Canada, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Rheumatology, University Health Network, Toronto, ON, Canada, 7Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANA, autoimmune diseases and cytokines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with Systemic Autoimmune Rheumatic Disease (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA) positive but lack clinical symptoms. It has been proposed that progression from asymptomatic autoimmunity to clinical disease is accompanied by immunologic changes that could be used as predictors of disease development. Our objective was to identify cyto/chemokine abnormalities in ANA+individuals who lack sufficient criteria for a diagnosis of SARD.

Methods: ANA+ individuals who: 1) lacked clinical symptoms of SARD (ANA No Symptoms, ANS); 2) had a least one clinical symptom of SARD (Undifferentiated Connective Tissue Disease, UCTD); or 3) had a recently diagnosed steroid and immunosuppressive naïve SARD were recruited, and compared with ANA– healthy controls (HC). The levels of 30 cyto/chemokines were measured, 29 by Luminex and one (BAFF) by ELISA. Peripheral blood interferon (IFN)-induced and BAFF gene expression was quantified by NanoString. The normalized levels of 5 ubiquitously expressed IFN-induced genes were summed to produce an IFN5 score.

Results: Cyto/chemokines were measured in plasma samples for 145 individuals (21 HC, 37 ANS, 28 UCTD, and 59 early SARD (6 SLE, 25 SjD, 25 SSc, and 3 MCTD/DM)). The plasma levels of four cyto/chemokines, IP-10, eotaxin, BAFF, and TNF-α, were significantly elevated in early SARD patients when compared to HC (Bonferroni corrected p = 0.0001, 0.0006, 0.003, 0.033, respectively). The levels of IP-10, eotaxin, and TNF-α were not significantly elevated in ANS and UCTD individuals as compared to HC. Although there was a trend to elevated serum BAFF levels in UCTD and ANS individuals, this only achieved statistical significance in UCTD patients (p = 0.037 and 0.065, respectively). However, ANS individuals had significant elevations of BAFF RNA in their peripheral blood (p = 0.009). We have previously reported that all ANA+ subgroups (ANS, UCTD and early SARD) have significantly elevated IFN5 scores. The levels of IP-10, serum BAFF, and BAFF RNA were positively correlated with IFN5 scores in ANA+individuals, suggesting that these pro-inflammatory factors are induced by type I IFN.

Conclusion: Although elevated levels of several pro-inflammatory factors are seen in early SARD patients, these factors are not elevated in ANA+ individuals who lack sufficient criteria for a diagnosis of SARD. Thus, elevations of pro-inflammatory factors appear to parallel progression to clinical disease.


Disclosure: W. Hafiz, None; N. H. Chang, None; B. Noamani, None; D. Bonilla, None; L. Lisnevskaia, None; E. Silverman, None; A. Bookman, None; S. R. Johnson, None; C. Landolt-Marticorena, None; J. Wither, None.

To cite this abstract in AMA style:

Hafiz W, Chang NH, Noamani B, Bonilla D, Lisnevskaia L, Silverman E, Bookman A, Johnson SR, Landolt-Marticorena C, Wither J. Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/lack-of-pro-inflammatory-cytochemokines-in-ana-individuals-with-insufficient-criteria-for-a-diagnosis-of-systemic-autoimmune-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-pro-inflammatory-cytochemokines-in-ana-individuals-with-insufficient-criteria-for-a-diagnosis-of-systemic-autoimmune-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology